Understanding how alpha-synuclein contributes to neurodegenerative diseases
Molecular mechanisms of alpha-synuclein induction and spread of pathobiology
['FUNDING_OTHER'] · UNIVERSITY OF FLORIDA · NIH-10560064
This study is looking at a protein called alpha-synuclein to understand how it contributes to memory and thinking problems in diseases like Alzheimer's, with the hope of finding new ways to help people who are affected by these conditions.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF FLORIDA (nih funded) |
| Locations | 1 site (GAINESVILLE, UNITED STATES) |
| Trial ID | NIH-10560064 on ClinicalTrials.gov |
What this research studies
This research investigates the role of the protein alpha-synuclein in the development and spread of neurodegenerative diseases, particularly those affecting memory and cognition like Alzheimer's disease. The study aims to identify the mechanisms that trigger the formation of harmful aggregates of this protein in the brain and how these aggregates can spread between cells. By using advanced monoclonal antibodies, researchers will explore different forms of alpha-synuclein to understand their unique properties and effects on disease progression. This could lead to new insights into potential therapeutic targets for patients suffering from these debilitating conditions.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or related neurodegenerative conditions.
Not a fit: Patients with neurodegenerative diseases not related to alpha-synucleinopathies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that slow down or prevent the progression of Alzheimer's disease and related disorders.
How similar studies have performed: Previous research has shown promising results in understanding the role of alpha-synuclein in neurodegenerative diseases, indicating that this approach has potential for significant breakthroughs.
Where this research is happening
GAINESVILLE, UNITED STATES
- UNIVERSITY OF FLORIDA — GAINESVILLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: GIASSON, BENOIT I — UNIVERSITY OF FLORIDA
- Study coordinator: GIASSON, BENOIT I
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Alzheimer disease dementia, Alzheimer syndrome, Alzheimer's Disease